<DOC>
	<DOCNO>NCT02454530</DOCNO>
	<brief_summary>The aim study describe real-life condition determinant use GCSF ( Granulocyte Colony-Stimulating Factor ) Nivestim® primary secondary prophylaxis patient receive chemotherapy solid tumour accord chemotherapy context : adjuvant metastatic setting .</brief_summary>
	<brief_title>Use Biosimilar Nivestim® Prevent Chemo-induced Neutropenia . Real Life Study</brief_title>
	<detailed_description>This longitudinal , observational , prospective , multicentre , cohort study , conduct France among representative sample public and/or private hospital-based oncologist . Data collect investigator three visit use data available patient medical record obtain patient question clinical examination perform consultation : - Baseline visit : prescription Nivestim® . - Follow-up visit : first cycle chemotherapy first course Nivestim® . - Final visit : last cycle chemotherapy 16-18 week inclusion .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Patients age least 18 year , see oncologist chemotherapy solid tumour . Patients oncologist decided initiation GCSF biosimilar treatment ( Nivestim® ) primary secondary prophylaxis . Patients inform computer process medical data right access correction . Patients contraindication use Nivestim® . Patients haematological malignancy include Myelodysplasia Chronic myeloid leukemia treat untreated . Patients participate participate previous month clinical trial . Patients refuse participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>